GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Itoco Inc (OTCPK:ITMC) » Definitions » Short-Term Debt

Itoco (ITMC) Short-Term Debt : $1.22 Mil (As of Sep. 2010)


View and export this data going back to 2009. Start your Free Trial

What is Itoco Short-Term Debt?

Itoco's Short-Term Debt for the quarter that ended in Sep. 2010 was $1.22 Mil.

Itoco's quarterly Short-Term Debt increased from Mar. 2010 ($1.08 Mil) to Jun. 2010 ($2.21 Mil) but then declined from Jun. 2010 ($2.21 Mil) to Sep. 2010 ($1.22 Mil).

Itoco's annual Short-Term Debt increased from . 20 ($0.00 Mil) to Dec. 2008 ($1.08 Mil) but then declined from Dec. 2008 ($1.08 Mil) to Dec. 2009 ($1.05 Mil).


Itoco Short-Term Debt Historical Data

The historical data trend for Itoco's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Itoco Short-Term Debt Chart

Itoco Annual Data
Trend Dec08 Dec09
Short-Term Debt
1.08 1.05

Itoco Quarterly Data
Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.01 1.05 1.08 2.21 1.22

Itoco Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Itoco Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Itoco's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Itoco (ITMC) Business Description

Traded in Other Exchanges
N/A
Address
50 West Liberty Street, Suite 880, Reno, NV, USA, 89501
Itoco Inc is focused on developing and bringing biotech products to the market via co-development and joint venture arrangements with various companies. The company is currently examining various technologies that seek to control and/or identify bio-contaminants such as viruses and bacteria.